NKTX250117P2500
- 0.25
- +0.07+38.89%
Nkarta Newsroom
Express News | Nkarta 13G Filing Shows Citadel Advisors Reported A 5.4% Stake In The Co As Of December 6, 2024
Express News | Kenneth Griffin Reports 5.4% Passive Stake in Nkarta as of Dec 6 - SEC Filing
Nkarta Opens Enrolment, Receives Clearance for Autoimmune Diseases Therapy Trials
Nkarta's Ntrust-2 Trial of NKX019 in Myasthenia Gravis Begins Enrollment
Express News | Nkarta Inc: Clinical Data From Ntrust-1 and Ntrust-2 Planned for 2025
Express News | Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta to Participate in an Upcoming Investor Conference
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
Nkarta Price Target Lowered to $16 From $20 at Mizuho
Nkarta Is Maintained at Outperform by Mizuho
Express News | Nkarta Inc : Mizuho Cuts Target Price to $16 From $20
Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
A Quick Look at Today's Ratings for Nkarta(NKTX.US), With a Forecast Between $11 to $18
Trending Stocks Today | Sunnova Energy International Inches up 3.82% Post-Market
Nkarta Ending Development of Asset for Lymphoma
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Cuts Target Price to $11
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Veeva Systems (VEEV)
Nkarta Is Maintained at Buy by Needham
Nkarta Analyst Ratings